Material and Method

Chemicals, bacterial strains and plasmids
Yeast extract, agar and tryptone were purchased from Roth (Germany), fatty acids (substrate and product ω-OHFA) and all other chemicals were acquired from Sigma-Aldrich (Germany). E. coli strain BL21 (DE3) was purchased from Novagen (Madison, WI, USA). The plasmid pET-30 containing the galactose oxidase mutant M [3] [4] [5] (GOase M3-5 ) gene was kindly provided by the Manchester Institute of Biotechnology, University of Manchester. 1 The plasmid pET-28a(+) (Novagen, Madison, WI, USA) with P450 BM3 from Bacillus megaterium and pET-28a(+) harbouring the fusion construct between the heme domain of CYP153A from Marinobacter aquaeolei and the reductase domain of P450 BM3 (CYP153A M.aq -CPR BM3 ) wild type and each variant from the mutant library were generated at the University of Stuttgart. 
Sequence alignments and designed primers
The substitutions selected for mutagenesis were based on amino acids frequencies deriving from conservation analysis in CYPs families. 3, 4 Site-directed mutagenesis was performed by QuikChange method to generate the small focussed library. 
Lysate preparation and in vitro performance
For the preparation of cell extract subsequently after the protein expression, the cells were centrifuged 
4.3.
Whole resting cell biotransformation
To perform whole resting cell biotransformations consequently after the protein expression the plates were centrifuged for 10 min at 2752 g and 4 °C. The medium was discarded and the cell pellets washed once with 2 mL of 100 mM potassium phosphate buffer pH 7.4. After centrifugation at 3000 g for 3 min, the cell pellets were resuspended in the same buffer to reach 100 g cww L -1
(corresponding to 1-2 mL buffer added). The biotransformations were performed with 1 mL of 50 g cww L -1 resting cells in the presence of C 12 and product 12-hydroxydodecanoic acid (ω-OHC 12 ), 5 % DMSO (v/v, not exceeding the solubility limit), for 2 h at 25 °C and 500 rpm. Negative controls were accomplished in the same fashion with the same concentration of organic co-solvent added. The reactions were stopped by centrifugation for 3 min at 3000 g and the supernatant was stored at -20 °C until further analysis.
Galactose oxidase assay
Prior to the GOase based assay, the cell-free supernatants from P450-catalysed reactions were treated at 90 °C for 30 min in order to deactivate potential additional metabolic activity. The GOase assay was 
CO spectra
The P450 protein concentration in whole cells was determined as described previously. 6, 7 One spatula of sodium dithionite was added to the sample prior to incubation on ice for 30 min ensuring a complete reduction of the heme domain. Subsequently, CO gas (except for the reference well) was applied to the reduced samples followed by incubation at 4 °C for 1 h. Plates were read on a plate reader in a range of λ = 400-500 nm.
GC-FID analysis
The samples were extracted twice with the same volume of methyl ter-butylether (MTBE Figure S1 . Heating step was applied to the supernatant following a 2 h biotransformation of 2 mM of C 12 substrate with resting E. coli cells (50 g cww L -1 ). This crucial step enables a maximum of absorption displayed after 1 h incubation via the GOase assay (blue curve) compared to 6 h in the absence of the heating step (red curve). Figure S2 . Increased concentrations of ω-OHC 12 applied to whole resting cell experiments after 2 h. A control assay (replacement of the product by the same volume of DMSO) was also implemented (grey circle). The intensity of the signal recorded via the assay correlates with the GC-FID analysis: a higher intensity of signal equals to a large amount of product formed. Figure S3 . Control reactions were tested in the absence of one of the following components: GOase, HRP, ABTS or ω-OHC 12 in comparison with a positive control containing each of the above mentioned ingredients. The GOase assay is only valid with the presence of each component. Figure S4 . Comparison of the product formation between CYP153A M.aq -CPR BM3 and P450 BM3 measured by the GOase assay and after extraction and analysis on GC-FID. Specific activity of the GOase towards ω-OHC 12 as a signal of absorption is displayed during the assay only for the product of CYP153A M.aq -CPR BM3 . P450 BM3 was shown active after GC-FID analysis, however the assay does not enable the detection of the product mixture ω-1, ω-2 and ω-3-OHC 12 . Table S3 . Positions selected for site-directed mutagenesis. The substitutions for the positions located in the active site were selected based on the results from a previous small focussed library targeting the binding pocket only. 8 To expand the diversity three positions from the substrate access tunnel were also addressed for mutation. 
ω-OHC 12 detection limit
Controls
Selectivity of the GOase M3-5
Small focussed mutant library
Positions
